IQVIA Holdings Inc. (NYSE: IQV) is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries. Headquartered in Durham, North Carolina, the company was formed in 2016 through the merger of Quintiles and IMS Health, initially operating as QuintilesIMS before renaming to IQVIA.
IQVIA operates three main divisions: Technology & Analytics (about 40% of revenues), offering health information technology, data analytics, and consulting; Research & Development (55%), functioning as a contract research organization managing clinical trials from phase I to IV, including data management and biostatistics; and Contract Sales & Medical (5%), providing sales and patient engagement services. With around 88,000-93,000 employees across more than 100 countries, IQVIA supports pharmaceutical, biotech, and medical device companies in drug development, commercialization, and market intelligence.
In the chemical sector relevant to pharmaceuticals, IQVIA offers Chemical Intelligence, a platform connecting buyers and sellers of active pharmaceutical ingredients (APIs), intermediates, and excipients, with data on over 489,000 chemicals, synthesis pathways, and global suppliers from 145 countries.
To provide comprehensive coverage, we aggregate data and news under the name IQVIA, encompassing the following company names, divisions, and related entities:
QuintilesIMS.
This list encompasses current and former names, alternate names, and key divisions associated with IQVIA, ensuring you can easily find all relevant information under a single, unified profile.
